Concepedia

Author

Grant D. MacLean

University of Alberta

Also Known As

G D MacLean, G MacLean, G. D. MACLEAN, G. D. MacLEAN, G. D. MacLean, G. D. Maclean, G. MacLean, G. Maclean, G.D. MACLEAN, G.D. Maclean

48

Publications

2.3K

Citations

25

H-Index

74

Concepts

All Affiliations

University of AlbertaCancer Institute (WIA)Alberta Cancer Foundation
GD

About

Grant D. MacLean is an author at University of Alberta specializing in medicine, immunology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

21

1.3K

2

Health Sciences

4

4

104

3

Arts

1

1

34

4

Public Health

1

1

34

5

Social Sciences

1

1

34

Grant D. MacLean

×

32

Publications

2.2K

Citations

24

H-Index

YearCitations

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

K. Swenerton, J Jeffrey, Gavin Stuart,

Journal of Clinical Oncology

1992

214

Antibodies Against Mucin-Associated Sialyl-Tn Epitopes Correlate with Survival of Metastatic Adenocarcinoma Patients Undergoing Active Specific Immunotherapy with Synthetic STn Vaccine

Grant D. MacLean, Mark A. Reddish, R. Rao Koganty,

Journal of Immunotherapy

1996

183

Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant

Grant D. MacLean, Mark Reddish, R. Rao Koganty,

Cancer Immunology Immunotherapy

1993

183

Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer

Martin Palmer, Joanne L. Parker, Shanu Modi,

Clinical Lung Cancer

2001

159

Enhancing the Effect of THERATOPE STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide

Grant D. MacLean, D.W. Miles, R.D. Rubens,

Journal of Immunotherapy

1996

157

Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide

Mark A. Reddish, Grant D. MacLean, R. Rao Koganty,

International Journal of Cancer

1998

129

Evidence of a Cellular Immune Response Against Sialyl-Tn in Breast and Ovarian Cancer Patients After High-Dose Chemotherapy, Stem Cell Rescue, and Immunization with Theratope STn-KLH Cancer Vaccine

Brenda M. Sandmaier, Dimitry V. Oparin, Leona Holmberg,

Journal of Immunotherapy

1999

120

Active Immunization of Human Ovarian Cancer Patients Against a Common Carcinoma (Thomsen-Friedenreich) Determinant Using a Synthetic Carbohydrate Antigen

Grant D. MacLean, M. B. Bowen-Yacyshyn, John Samuel,

Journal of Immunotherapy

1992

120

Survival patterns in biliary atresia and comparison of quality of life of long-term survivors in Japan and England

E R Howard, Grant D. MacLean, Masaki Nio,

Journal of Pediatric Surgery

2001

94

Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69 + lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy

Mark A. Reddish, Grant D. MacLean, Sibrand Poppema,

Cancer Immunology Immunotherapy

1996

84

Page 1